ABSTRACT - GlaxoSmithKline says Serevent, one of its popular asthma drugs, may pose risk of death or serious illness in certain patients; halts study of drug, but says it will work with regulators to design further studies to address safety concerns; Food and Drug Administration issues statement emphasizing that benefits of Serevent outweigh risks (M) GlaxoSmithKline said yesterday that Serevent, one of its popular asthma drugs, might pose a risk of death and serious asthma-related illness in some patients.

PURCHASING FROM NYTIMES.COM IS QUICK AND SECURE.
To read the complete article, simply click on one of the BUY NOW buttons below. You can buy this single article or, for even greater value, you can purchase this article as part of a multi-pack. You'll then have the opportunity to buy additional articles now or in the future at significant savings!
Purchase Single Article -- $2.95
Purchase as part of Article 4-Pack -- $7.95 ($1.99/article - a 33% savings!) Pack expires after 1 month
Purchase as part of Article 10-Pack -- $15.95 ($1.60/ article - a 46% savings!) Pack expires after 3 months
Purchase as part of Article 25-Pack -- $25.95 ($1.05/ article - a 65% savings!) Pack expires after 6 months

How multi-packs work: A multi-pack is an archive package that saves you money by allowing you to pre-purchase a set number of articles in bulk at a reduced price. You can then debit from your multi-pack and quickly access articles from the archive at your convenience over the lifetime of the multi-pack.

Once you purchase an article, you may view it as often as you like over the next 90 days. Archive articles do not include photos, charts or graphics